Ipsen

IPN

FR0010259150

Ipsen specialises in the research, development, manufacture and marketing of specialty medicines. Net sales by therapeutic area break down as follows: - oncology (75.2%); - neuroscience (21.1%); - rare diseases (3.7%). At the end of 2023, the group had 4 research and development centres located in France, the United Kingdom, the United States and China, and 4 manufacturing sites worldwide. Net sales are distributed geographically as follows: Europe (40.2%), North America (33.3%) and other (26.5%).

Sector

Pharmaceuticals

Calendar

2024-07-23 - Q2 2024 Earnings Release

Related indices

STOXX EUROPE 600 (EUR) , CAC Mid 60

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

IPSEN : Better-than-expected Q1; guidance unchanged

April 24, 2024 at 10:50 am EDT

More Strategies

Ratings for Ipsen

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

111.6 EUR

Average target price

127.3 EUR

Spread / Average Target

+14.05%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
IPSEN	+3.43%	10.05B
ELI LILLY AND COMPANY	+62.66%	854B
NOVO NORDISK A/S	+40.42%	636B
JOHNSON & JOHNSON	-4.37%	361B
MERCK & CO., INC.	+17.16%	324B
ABBVIE INC.	+9.87%	301B
ASTRAZENECA PLC	+15.66%	247B
ROCHE HOLDING AG	+4.21%	230B
NOVARTIS AG	+17.90%	228B
AMGEN INC.	+14.86%	177B

Other Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 11:35:23 2024-07-12 am EDT			5-day change	1st Jan Change
111.6 ^EUR	-0.09%		+0.36%	+3.43%

Jul. 11	CAC40: maintains gains after reassuring US inflation figures	CF
Jul. 11	CAC40: rise without volume, W-Street at its zenith but falls back	CF

CAC40: maintains gains after reassuring US inflation figures	Jul. 11	CF
CAC40: rise without volume, W-Street at its zenith but falls back	Jul. 11	CF
CAC40: over 7600pts before US inflation figures	Jul. 11	CF
Ipsen: worldwide licensing agreement with Foreseen	Jul. 11	CF
Ipsen, Foreseen Biotechnology Ink Exclusive Global Licensing Deal for Antibody-drug Conjugate	Jul. 11	MT
Markets Powered by Alternating Current	Jul. 10
Hutchmed Shares Rise After Tazemetostat Gets Priority Review Status in China	Jul. 05	MT
Ipsen Expands Partnership with Exelixis for Cabometyx	Jul. 02	MT
Ipsen extends collaboration with Exelixis	Jul. 02	CF
IPSEN : UBS remains positive ahead of quarterly results	Jun. 26	CF
Ipsen: share price soars, UBS confirms its recommendation	Jun. 12	CF
IPSEN : UBS remains Buy after FDA approval	Jun. 12	CF
Genfit S.A. Announces the Successful Corporate Milestone with U.S. FDA Accelerated Approval of Ipsen's Iqirvo for Primary Biliary Cholangitis	Jun. 11	CI
Ipsen: FDA grants approval for treatment	Jun. 11	CF
Ipsen Secures US FDA's Accelerated Approval for Liver Disease Drug Iqirvo	Jun. 11	MT
Genfit Partner Ipsen Gets FDA Accelerated Approval for Primary Biliary Cholangitis Treatment	Jun. 10	MT
Ipsen's Rare Liver Disease Treatment Gets FDA OK	Jun. 10	DJ
US FDA grants accelerated approval to Genfit and Ipsen's liver disease drug	Jun. 10	RE
US FDA approves Genfit and Ipsen's liver disease drug	Jun. 10	RE
Ipsen Expands Oncology Research Collaboration with Marengo Therapeutics	Jun. 07	MT
Ipsen: research partnership with Marengo extended	Jun. 07	CF
Ipsen Hires New Chief Corporate Affairs Officer	Jun. 06	MT
Ipsen: new Chief Corporate Affairs Officer	Jun. 06	CF
Ipsen: new positive data in PBC	Jun. 05	CF
Ipsen: mandate to an ISP for share buybacks	Jun. 03	CF